Skip to main content

Table 4 The relationship between clinicopathological factors and the expression level of (a) PD-L1 in NPCs, (b) PD-1 in NPCs

From: The prognostic significance of PD-L1 and PD-1 expression in patients with nasopharyngeal carcinoma: a systematic review and meta-analysis

Clinicopathological factors RR 95% CI p value Heterogeneity No. of studies Statistical model used
I2 (%) p value
(a)
 Gender: male 1.02 (0.96, 1.09) 0.45 0 0.70 13 Fixed
 T stage ≥ 3 1.00 (0.89, 1.13) 0.88 42 0.07 11 Random
 N stage ≥ 2 0.98 (0.87, 1.10) 0.77 34 0.12 11 Fixed
 Metastasis 0.83 (0.52, 1.33) 0.45 0 0.45 4 Fixed
 Stage III or IV 1.07 (0.99, 1.15) 0.08 38 0.12 9 Fixed
 Undifferentiated 0.99 (0.84, 1.18) 0.94 54 0.07 5 Random
 Tobacco use: smoker 0.91 (0.78, 1.07) 0.24 0 0.43 8 Fixed
 Alcohol use: drinker 0.73 (0.49, 1.09) 0.13 0 0.63 2 Fixed
 EBV positive 1.03 (0.93, 1.15) 0.54 29 0.24 2 Fixed
(b)
 Gender: male 1.04 (0.96, 1.13) 0.35 0 0.99 6 Fixed
 T stage ≥ 3 0.93 (0.81, 1.07) 0.29 0 0.66 4 Fixed
 N stage ≥ 2 1.11 (0.95, 1.29) 0.20 0 0.97 5 Fixed
 Stage III or IV 1.02 (0.94, 1.10) 0.65 29 0.23 5 Fixed
 Tobacco use: smoker 1.10 (0.85, 1.43) 0.46 0 0.85 3 Fixed
 PD-L1 positive 1.25 (1.02, 1.52) 0.03 0 0.80 4 Fixed
  1. RR: relative risk; CI: confidence interval; No: number; NPC: nasopharyngeal carcinoma; EBV: Epstein–Barr virus